GlassScriptPhysician profile
Aprile C Gilmore
NPI 1144517541
$4,002.92
in general payments reported to CMS, 2019-2025
24 companies · $867 in 2025
The $867 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $106 · 2021: $648 · 2022: $452 · 2023: $605 · 2024: $905 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,343 · Debt Forgiveness: $34.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,342.91 |
| Debt Forgiveness | $34.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $470.30 | 2019-2024 | Jornay Pm |
| Corium, LLC | $453.81 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $436.13 | 2021-2025 | Qelbree |
| Pfizer INC. | $400.19 | 2019-2025 | |
| Tris Pharma INC | $374.71 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $287.74 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $251.30 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $231.62 | 2019-2025 | Bexsero, Pediarix, Menveo |
| Collegium Pharmaceutical, INC. | $213.38 | 2025 | Jornay Pm |
| Sobi, INC | $152.49 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $124.64 | 2024-2025 | Dupixent |
| Sanofi Pasteur INC. | $119.35 | 2021-2025 | |
| Baxter Healthcare | $108.95 | 2022-2023 | |
| Shire North American Group INC | $75.30 | 2019 | |
| Qol Medical, LLC | $72.30 | 2022-2025 | Sucraid, Sucraid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $57.62 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $33.83 | 2023-2024 | Flumist Quadrivalent |
| Genzyme Corporation | $33.67 | 2019 | |
| Neos Therapeutics, LP | $29.46 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.49 | 2024 | |
| Novo Nordisk INC | $17.24 | 2025 | Wegovy |
| Ibsa Pharma INC. | $15.63 | 2022 | |
| Aytu Biopharma, INC. | $14.10 | 2025 | |
| Pbg Puerto Rico LLC | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aprile Gilmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.